Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 8/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.71 |
| ▸ | ACLY | P53396 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599512 | 0.91 | KEAP1 (0.71) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17599511 | 0.91 | KEAP1 (0.71) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17612854 | 0.91 | KEAP1 (0.59) | KEAP1NFE2L2ACLYNOTUMCCR2 | |
| SCHEMBL17599497 | 0.89 | KEAP1 (0.75) | KEAP1NFE2L2ACLYNOTUMCCR2 | |
| SCHEMBL17599484 | 0.85 | KEAP1 (0.70) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17599422 | 0.85 | KEAP1 (0.70) | KEAP1NFE2L2NOTUM | |
| SCHEMBL24812743 | 0.84 | KEAP1 (0.87) | KEAP1NFE2L2NOTUM | |
| SCHEMBL29584677 | 0.83 | KEAP1 (1.00) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17599452 | 0.83 | KEAP1 (1.00) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17599442 | 0.83 | KEAP1 (1.00) | KEAP1NFE2L2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997966-A1 | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | claimed |
| EP-2997966-A1 | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |